Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-(±)-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-(±)-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.


Pharmaceutical Technology


Solubility studies. Because of the expensive nature of (R, S)-(±)-sodium ibuprofen dihydrate, its solubility was determined by the gravimetric titration method that required a relatively small amount of material (13). Although the gravimetric titration method had an inherent error of about ± 20% because the solvent volume used was assumed to be the same as the solution volume (13) and was less accurate than the well-known UV-visible spectroscopic technique (16) and the evaporation-weighing technique (17), it was rapid, robust, and more suited for the initial screening. Unlike the other two techniques, the gravimetric titration method did not require establishing time-consuming calibration curves of (R, S)-(±)-sodium ibuprofen dihydrate concentration in every solvent and did not produce any unforeseen solvates that could interfere with the true mass of the dihydrate solids after removal of the solvents.

Solvent-miscibility studies. The miscibility tests were performed by mixing two solvents from the 23 solvents in a 20-mL scintillation vial (13). The number of miscible and immiscible solvent pairs from the miscibility investigations and the API solubility in the 23 single solvents from the Solubility Studies Section (13) were combined to deduce a form space. The form space is defined as the total number of solid-generation experiments in pure-solvent, cosolvent and antisolvent systems (13).

Polymorph, crystallinity, and crystal-habit studies. Solids were produced in the good solvents ferreted out by the Solubility Studies Section (13). The polymorphism, crystallinity, and crystal habit of the solids were determined by DSC, TGA, PXRD, OM, and SEM, respectively.

Scanning electron microscopy. Solids of racemic (R, S)-(±)-sodium ibuprofen dihydrate compound grown from water were filtered, rinsed with acetone, and vacuumed-dried at 40 °C or 4 h. The anhydrous (R, S)-(±)-sodium ibuprofen solids were mounted on an aluminum stub by a double-sided carbon conductive adhesive tape (Product number 16073, Ted Pella Inc., Redding, CA). The solid sample was sputter-coated with a 6-nm thick gold film in an Hitachi E-1010 Auto Sputter Coater (Hitachi Ltd., Tokyo, Japan).

SEM was carried out using an Hitachi S-3500N (Hitachi Ltd., Tokyo, Japan) instrument equipped with a tungsten filament cathode source. Gold-coated samples were examined with beam energies of 15 kV with a chamber pressure of 10-5 Pa (resolution ~3Å at these voltages).

Drying-scheme studies. Filtered solids of the racemic (R, S)-(±)-sodium ibuprofen dihydrate compound were dried by three various modes in a DOV-40 oven (Dengyng Instrument Co., Ltd., Taiepi, Taiwan) at 40 °C for 4 h in air, at 40 °C for 4 h under vacuum, and 90 °C for 2 h under vacuum. A vacuum of 6.7 × 10-2 Pa was generated by the GVD-050A vacuum pump (Ulvac Kiko Inc., Yokohama, Japan).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here